Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action
Sheng-Min Wang, Changsu Han, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masand, Chi-Un Pae
Psychiatry Investig. 2015;12(2):155-163.   Published online 2015 Mar 18     DOI:
Research on Network Service Management Platform for Long Term Mechanism of Sports in Colleges
Hongyuan He, Tao He, Gang Peng
Wireless Personal Communications.2018; 102(2): 1117.     CrossRef
Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review
Sheng-Min Wang, Changsu Han, Won-Myoung Bahk, Soo-Jung Lee, Ashwin A. Patkar, Prakash S. Masand, Chi-Un Pae
Chonnam Medical Journal.2018; 54(2): 101.     CrossRef
5-HT1A receptor ligands and their therapeutic applications: review of new patents
Jakub Staroń, Ryszard Bugno, Adam S. Hogendorf, Andrzej J. Bojarski
Expert Opinion on Therapeutic Patents.2018; 28(9): 679.     CrossRef
Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity
Alaeddine Djillani, Mariel Pietri, Sébastien Moreno, Catherine Heurteaux, Jean Mazella, Marc Borsotto
Frontiers in Pharmacology.2017;[Epub]     CrossRef
Identification and characterization of vilazodone metabolites in rats and microsomes by ultrahigh-performance liquid chromatography/quadrupole time-of-flight tandem mass spectrometry
Balasaheb B. Chavan, Pradipbhai D. Kalariya, Shristy Tiwari, Rakesh D. Nimbalkar, Prabha Garg, R. Srinivas, M.V.N. Kumar Talluri
Rapid Communications in Mass Spectrometry.2017; 31(23): 1974.     CrossRef
Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: A meta-analysis
Nicholas Zareifopoulos, Irene Dylja
Asian Journal of Psychiatry.2017; 26: 115.     CrossRef
New drugs in psychiatry: focus on new pharmacological targets
Filippo Caraci, Gian Marco Leggio, Salvatore Salomone, Filippo Drago
F1000Research.2017; 6: 397.     CrossRef
Vilazodone for major depressive disorder in adults
Lin Song, Yao Liu, Fang Liu, Ruoqi Zhang, Huanhuan Ji, Yuntao Jia
Cochrane Database of Systematic Reviews.2016;[Epub]     CrossRef
P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood–brain barrier in vivo
Christoffer Bundgaard, Elin Eneberg, Connie Sánchez
Neuropharmacology.2016; 103: 104.     CrossRef
Vilazodone for the Treatment of Depression: An Update
Sheng-Min Wang, Changsu Han, Soo-Jung Lee, Ashwin A. Patkar, Prakash S Masand, Chi-Un Pae
Chonnam Medical Journal.2016; 52(2): 91.     CrossRef
Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice
Changsu Han, Sheng-Min Wang, Soo-Jung Lee, Tae-Youn Jun, Chi-Un Pae
Chonnam Medical Journal.2015; 51(2): 66.     CrossRef
Five potential therapeutic agents as antidepressants: a brief review and future directions
Sheng-Min Wang, Changsu Han, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masand, Chi-Un Pae
Expert Review of Neurotherapeutics.2015; 15(9): 1015.     CrossRef
Vilazodone: A Review in Major Depressive Disorder in Adults
Paul L. McCormack
Drugs.2015; 75(16): 1915.     CrossRef
Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded,prospective study
Changsu Han, Sheng-Min Wang, Kyung-Phil Kwak, Wang-Yeon Won, HwaYoung Lee, Chia Ming Chang, Tze Chun Tang, Chi-Un Pae
Journal of Psychiatric Research.2015; 66-67: 84.     CrossRef
Dominios cognitivos en la depresión unipolar. Teorías multimodales y nuevas perspectivas terapéuticas
Cristóbal Gastó, Joana Guarch, Víctor Navarro
Psiquiatría Biológica.2015; 22(2): 33.     CrossRef